what are glp 1 agonists GLP-1 receptor show promise in treating substance use disorders Glucagon-like peptide-1 - Wikipedia
Description
10.1038/nrgastro.2016.107 [DOI] [PMC free article] [PubMed] [Google Scholar] Rebosio C., Balbi M., Passalacqua M., Ricciarelli R., Fedele E
Phase three of the clinical trials was conducted using semaglutide concentrations ranging from 0.5 to 2.0 mg for 30104 weeks
So the order from the gut gives the signal but doesnt decide what is actually going to happen
95% CI, 0.72-0.9
& Abdelghany, R
While LBM loss was evident, it was relatively modest compared to body mass loss
